Navigation Links
Regenerative Medicine Company, Eqalix, Announces Grant from Nanotechnology Institute in Philadelphia, Pennsylvania
Date:3/26/2013

Reston, VA (PRWEB) March 26, 2013

Eqalix has announced they have received a $50,000 grant from the Nanotechnology Institute in Philadelphia Pennsylvania which will facilitate the advancement of the development of its technologies for regenerative medicine. This project was financed (in part) by a grant from the Commonwealth of Pennsylvania, Department of Community and Economic Development via funding to the Ben Franklin Technology Partners of Southeastern PA and the Nanotechnology Institute. This grant comes from its Match for Sponsored Research Program, which adds to the $125,000 Sponsored Research Agreement executed between Eqalix and Temple University. This SRA is designed to facilitate the expansion of Eqalix’s pre-clinical research and development efforts through a Sponsored Research Agreement with Temple University’s Department of Bioengineering.

"The NTI has been a continuous and enthusiastic supporter of Dr. Peter Lelkes and his NanoScaffold technology. The successful execution of the licensing and SRA agreements for this technology moves this important technology in medical textiles closer to commercialization." Anthony P. Green, Ph.D., Vice President of Technology Commercialization: Life Sciences, BFTP/SEP, Ben Franklin Director, NTI.

As a first goal, the NTI Grant will be used to advance research and development of a novel plant-protein based nano-fibrous scaffold for difficult to treat wounds as well as applications in aesthetic dermatology. Scaffolds made of plant proteins are intended to accelerate the natural wound healing process and are a promising product candidate for skin regeneration in acute and chronic in wounds and burns. To date, Eqalix’s APS for enhanced wound healing have undergone the initial proof-of concept in pre-clinical research. Joseph P. Connell, Chairman and CEO stated, “We are excited to receive the financial support of NTI to advance the development of OmegaSkin™. OmegaSkin™ has the potential to heal full thickness wounds without scarring and has the potential to change the way we treat chronic wounds, burns and accelerate the physiologic healing in aesthetic dermatology applications.”

About Eqalix
Eqalix is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing novel nano-materials for the repair and regeneration of diseased, traumatized and aging tissues. Its innovative technologies are intended to revolutionize the unmet needs in multiple commercial and therapeutic applications in the Regenerative Medicine space via exclusive commercial licensing from three prominent institutions (University of Pennsylvania, Drexel University and Children’s Hospital of Philadelphia).

Eqalix plans to leverage its technologies to develop and commercialize: (a) plant-protein based nano-fiber scaffold for use in aesthetic dermatology and wound healing markets; (b) small- diameter hybrid vessels that reduce graft thrombogenicity and promote the creation of a functional endothelium after implantation; and (c) 3-Dimensional tissue scaffolds with tunable properties for tissue and organ replacement and repair in vivo and for advancing molecular cell science and engineering in vitro.

About NTI:
The overarching mission of NTI is to focus on the transfer of nanotechnology discoveries and intellectual knowledge from universities to industry partners, and on the rapid application and commercialization of nanotechnology to stimulate economic growth.

The NTI is seeded with a technology grant whose cumulative value is $16.3 million from the Commonwealth of Pennsylvania’s Ben Franklin Technology Development Authority, and is administered through the Department of Community and Economic Development (DCED).

The NTI breaks barriers to commercialization through facilitated licensing, sponsored research and company spinouts through partnering organizations. With its unique model, the NTI acts as a “single point of contact” that brings together academic and research institutions, corporate partners, private investors, government, and economic development organizations to harness the potential of this new scientific frontier.

Eqalix, Inc. is a privately held Virginia based C-Corporation located at:
1900 Campus Commons Drive
Suite 100
Reston, VA 20191
Contact: Joseph P. Connell, CEO
910.233.0806

Read the full story at http://www.prweb.com/releases/2013/3/prweb10554084.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
2. ODT Forum Presents Regenerative Technologies
3. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
4. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
5. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
6. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
7. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte
11. Stem Cell / Regenerative Medicine & HSCT / Cord Blood Market Analysis in New Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):